Atieh Karimzadeh: Romiplostim Shows High Response and Reduced Bleeding in Pediatric HSCT
Atieh Karimzadeh, Postdoctoral Research Fellow at the Pediatric Cell and Gene Therapy Research Center, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Transplantation and Cellular Therapy, adding:
“Excited to share another publication from our team!
Our study, ‘Efficacy and Safety of Romiplostim in Treating Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatric Patients‘, has been published in the Transplantation and Cellular Therapy (Q1, IF=4.4)
In the largest prospective pediatric study to date on this topic, we found that romiplostim achieved an impressive 80.9% response rate, significantly reduced bleeding events, and
helped most patients become transfusion-independent – all with an excellent safety profile.
These findings highlight the potential of romiplostim as an effective supportive care strategy for children experiencing prolonged thrombocytopenia after HSCT.
Special thanks to Amir Ali Hamidieh and Maryam Behfar for their invaluable mentorship, guidance, and support throughout this project.
Shout out to the brilliant Zahra Karimizadeh for this amazing collaboration.
Proud to contribute to advancing pediatric HSCT research and improving patient outcomes.”
Title: Efficacy and Safety of Romiplostim in Treating Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Arm Clinical Trial
Authors: Zahra Karimizadeh, Maryam Behfar, Atieh Karimzadeh, Leila Jafari, Amirali Kalantari, Zeynab Nikfetrat, Amir Ali Hamidieh
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI